Olcegepant

SKU: orb1309304

Description

Olcegepant (BIBN-4096) is a potent and highly selective small-molecule antagonist of the human CGRP1 receptor, exhibiting sub-nanomolar affinity (Ki = 14.4 pM). It is widely used in migraine research to investigate CGRP receptor function in both in vitro binding assays and in vivo animal models of neurogenic inflammation and vasodilation.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Images & Validation

−

Key Properties

−

CAS Number	204697-65-4
MW	869.65
Purity	98.16% (May vary between batches)
Formula	C₃₈H₄₇Br₂N₉O₅
SMILES	O=C1N(CC=2C(N1)=CC=CC2)C3CCN(C(N[C@H](CC4=CC(Br)=C(O)C(Br)=C4)C(N[C@H](C(=O)N5CCN(CC5)C=6C=CN=CC6)CCCCN)=O)=O)CC3
Target	CGRP Receptor
Solubility	DMSO:23.81 mg/mL (27.38 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.3 mM)

Bioactivity

−

Target IC50	CGRP (human):14.4 pM (ki)\|CGRP1:0.03 nM
In Vivo	Pre-treatment with Olcegepant (900 μg/kg) inhibits capsaicin-induced Fos expression in the spinal trigeminal nucleus by 57%, without altering phosphorylated extracellular signal-regulated kinase expression in the trigeminal ganglion. Olcegepant (1-30 μg/kg, i.v.) suppresses CGRP effects on facial blood flow in marmosets and significantly reduces mechanical allodynia in CCI-ION rats (0.3-0.9 mg/kg, i.v.). Additionally, Olcegepant (0.6 mg/kg, i.v.) decreases c-Fos immunolabeled cells and ATF3 transcript upregulation, but not interleukin-6, in the trigeminal ganglion of CCI-ION rats .
In Vitro	Olcegepant exhibits exceptional efficacy at primate CGRP receptors, demonstrating a high affinity (Ki) of 14.4±6.3 (n=4) pM for human CGRP receptors, surpassing that of the endogenous ligand CGRP and demonstrating a 150-fold greater affinity than the peptidic antagonist CGRP8-37. It competitively antagonizes CGRP-induced concentration-dependent relaxation, effectively reversing CGRP-mediated vasodilation in human cerebral vessels and inhibiting neurogenic vasodilation in a surrogate animal model for migraine pathophysiology. This suggests that Olcegepant, acting as a CGRP receptor antagonist, may be a potential novel abortive treatment for migraines. Its competitive antagonism has also been confirmed in SK-N-MC cells, with its effects observed in isolated human cerebral, coronary, and omental arteries using sensitive myograph techniques.

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

BIBN 4096, BIBN 4096BS, BIBN4096, BIBN-4096, Calcitonin gene-related peptide receptor, CGRP1, CGRPReceptor, CGRP Receptor, Olcegepant, inhibit, Inhibitor, hCGRP

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

6918509 ↗

Key Properties

−

No computed properties available.

Protocol Information

Find More Protocols

Purity:	99.69% (May vary between batches)
CAS Number:	586368-06-1
MW:	906.11
Formula:	C₃₈H₄₈Br₂ClN₉O₅

Olcegepant

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Olcegepant hydrochloride [orb1708988]

Quality Guarantee

Compound Identifiers

Key Properties

Protocol Information

Available Sizes

Email

UK Office

US Office

CN Office

Distributors